Broadwood Partners commented on what it called “increasing public opposition” to the proposed acquisition of STAAR Surgical (STAA) by Alcon (ALC). President and founder of Broadwood, Neal Bradsher stated, “It is clear the sale process that led to this proposed transaction was deeply flawed and conflicted from the beginning. This proposed transaction comes at the wrong time, following the wrong process, and at the wrong price. All three major shareholder advisory firms agree, in a rare example of unanimity among these independent experts. So too do numerous shareholders. We continue to urge our fellow shareholders to vote ‘AGAINST’ the proposed transaction on the GREEN Proxy Card.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical reports preliminary Q3 revenue $94.7M, consensus $92.15M
- Broadwood urges shareholders vote ‘AGAINST’ acquisition of STAAR by Alcon
- Staar Surgical says no acquisition proposals received except from Alcon
- Broadwood: Proxy advisory firms recommend Staar shareholders vote against sale
- STAAR Surgical Faces Legal Challenges in Alcon Merger